Trials / Completed
CompletedNCT01844661
Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors.
Phase 1 Trial of Celyvir in Children and Adults With Metastatic and Refractory Solid Tumors.
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Hospital Infantil Universitario Niño Jesús, Madrid, Spain · Academic / Other
- Sex
- All
- Age
- 6 Months – 75 Years
- Healthy volunteers
- Not accepted
Summary
The investigators will evaluate the safety of weekly infusions (n=6) of CELYVIR in children and adults with metastatic and refractory solid tumors. CELYVIR consists in bone marrow-derived autologous mesenchymal stem cells (MSCs) infected with ICOVIR5, an oncolytic adenovirus. In addition to data on toxicities the investigators will evaluate clinical response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CELYVIR |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2014-12-01
- Completion
- 2016-01-01
- First posted
- 2013-05-01
- Last updated
- 2016-02-19
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT01844661. Inclusion in this directory is not an endorsement.